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ABSTRACT
OBJECTIVE: HDACs are among transcriptional regulatory elements that regulate key features of proliferation 
and differentiation in all cell types including cancerous. They may also interfere in such stages of cancer de-
velopment as migration, invasion, multi-drug resistance and angiogenesis. Proven information about HDAC1 
role in development of bladder cancer is limited only to cell lines in vitro. The lack of a comprehensive clinical 
in vivo study led us to evaluate HDAC1 expression in human clinical specimens.
METHODS: We analyzed a large group of bladder cancer patients. The presence of hHDAC1 mRNAs were 
tracked using specifi c HDAC1 primers in cancer samples and the quantity of HDAC1 transcripts were quantifi ed 
using real time qPCR method and was compared to those of normal bladder samples from healthy patients.
RESULTS: HDAC1 mRNA expression was signifi cantly elevated in Bladder cancer specimens. To our knowl-
edge, this result is the fi rst, showing an elevation in vivo in HDAC1 mRNA levels in clinically cancerous tissue 
of patients with bladder cancer.
CONCLUSIONS: We conclude that hHDAC1 overexpression might be implicated in bladder cancer tumorigenesis 
and that the over-expressed HDAC1 mRNA might be a potential diagnostic marker and, a target for treatment 
of bladder cancer using HDACi-drugs in future (Tab. 2, Fig. 2, Ref. 30). Text in PDF www.elis.sk.
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Introduction
Bladder cancer is the 9th most frequent cancer in men and the 
17th most frequent cancer in women (1). Populations of North 
America, Northern Africa and Europe have the highest incidence 
rates of this malignancy. Most of bladder cancer cases are super-
fi cial subtype, while approximately 20–40 % of the patients will 
develop invasive cancer. Bladder cancer includes heterogeneous 
morphological categories: More than 90 % of bladder cancer cases 
are urothelial carcinoma, whereas adenocarcinoma, squamous cell 
carcinoma, small cell carcinoma and other subtypes are rare (2). 
Although around 20 % of non-invasive and stroma invasive tumors 
are cured, 60–70 % recur at least once in 5 years and 10–20 % 
progress to muscle invasive cancer after the fi rst removal (3). Epi-
genetic events such, as histone acetylation/deacetylation, control 
transcriptional status of genes that play vital roles in development 
of the cancer (4). Acetylation and deacetylation occur by function 
of Histone Acetyl Transferases (HATs) and Histone Deacetylases 
(HDACs), respectively. Whereas acetylation induces remodeling 
of core nucleosome and transcriptional activation, the deacetylation 
of histone tails results in chromatin condensation, which in turn, 
causes repression of transcription (5). N-terminal tails of the core 
histones H2A, H2B, H3 and H4 are the best known substrates for 
these enzymes. Non-histone proteins can also be altered in their 
function by acetylation and deacetylation (6). HDACs are grouped 
into four classes of I, II, III and IV (7). Eleven family members of 
Class I, II and class IV are called as “classical” HDACs, whereas 
class III members are named Sirtuin proteins (7). Inside HDAC 
family, the cellular and biochemical functions of HDAC1 are 
relatively well studied. HDAC1 is a highly conserved enzyme 
presented in the cell nucleus of all tissues and, participates in both 
proliferation and cell death (8). This enzyme is associated with 
nuclear multi protein complexes that are important elements for 
repression of transcription and epigenetic modifi cations (9). This 
means that HDAC1 acts in a complex enzymatic structure. Besides 
HDAC1, it has recently been shown that other HDACs might also 
interfere in such cancerous cells functions such as: differentiation, 
cell cycle arrest and apoptosis, as well as migration, invasion, 
multi-drug resistance and angiogenesis. Apparently, functions of 
HDACs are not redundant and the cancer cells clearly are unable 
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to compensate an absence of a given HDAC (10). According to 
the most studies, HDAC1 has a crucial role in developing and pro-
gression of different human cancer types and its over-expression 
may be associated with tumor growth and a poor prognostic fac-
tor in many malignancies (11). Over-expression of HDAC1 has 
been reported in gastric, pancreatic and prostatic cancers and, it 
is shown to be a prognostic factor in breast and prostatic tumors 
(4, 11–13). In exocrine pancreatic epithelial cancer, cells lacking 
HDAC1 are enlarged and fl attened with an irregular shape with 
additionally cytoplasmic vacuoles and micronuclei (4). It seems 
HDAC1 is needed for inhibiting the cancer cells from starting a 
state of permanent cell division stop, such as: mitotic catastrophe 
and cellular senescence (14). Acetylation of histones H3 and H4 
and regulating expression of CDK inhibitors are among mecha-
nisms of HDAC1, which mediates these functions (4). Many re-
searchers introduced class I HDACs as the most functional target 
for cancer therapy because HDAC inhibitors (HDACi) with the 
activity against class I family usually present major anti-prolifer-
ative and apoptosis-inducing effects (10). In addition, anti-tumor 
effects of HDACi might be extended by blocking deacetylation 
of various proteins involved in tumorigenesis (15). Such effects 
caused by HDAC inhibitors are of great interest of developing 
HDAC inhibitors as novel anticancer drugs and several HDACi 
have recently been introduced, which selectively inhibit only the 
class I enzymes; especially HDAC1 (16). Various other HDAC 
inhibitors are currently being tested in clinical trials and some 
have been approved for clinical treatments by FDA (U.S. Food 
and Drug Administration) (17).
Our goal in this study was to evaluate HDAC1 mRNA expres-
sion changes in Bladder tissues in patients with cancer. We have 
analyzed a large clinically characterized group of patients with 
bladder cancer and measured the expression levels of HDAC1 
mRNA in clinical specimen. Based on our result, we speculate that 
in the future, HDAC1 can be introduced as a prognostic biomarker 
in the bladder cancer diagnosis and, a potential HDACi-drug target 
in the treatment for this type of cancer.
Material and methods
Patient characteristics
88 patients diagnosed with bladder cancer at Razi and Aria hos-
pitals in Rasht, Guilan, Iran, aged from 42 to 90 years old (median 
65.5) participated in the current study. Of that, 76 were male and 
12 were female. 79 samples were collected from normal bladder 
tissues of 66 men and 13 women, aged from 38 to 87 years (me-
dian 61.3 years old). All patients signed an informed consent in 
order to give the permission of using their Bladder tissues. This 
study has been approved by Guilan Medical Sciences University 
Ethics Committee.
Tissue and clinicopathological data
Cancerous tissues of bladder were collected after Transure-
thral Resection (TUR) and/or biopsies and normal tissues of blad-
der were collected after “scrutiny” biopsies. Fresh tissues were 
snap-frozen in liquid nitrogen and stored at –80 °C until entering 
laboratory process. Systematic histopathological analysis of the 
biopsies was performed in the same time as the freezing in liquid 
nitrogen. All bladder tumor samples were examined to determine 
the grade of respective Bladder carcinoma. Of 88 cancer samples, 
37 showed low grade tumors whereas 51 were diagnosed to be 
higher grade. Clinicopathological data of the patients in current 
study showed that muscle invasion occurred in 18 patients, while 
it was absent in the rest of 70 cases. Control samples were from 
“scrutiny” biopsies of normal bladder parenchyma collected from 
the patients with bladder objection, but without showing any type 
of bladder cancers. A part of normal bladder control samples were 
obtained through open transurethral prostatectomy. The cancerous 
samples were categorized into a low-to high grade groups accord-
ing to the 2004 WHO (World Health Organization) classifi cation 
of urothelial neoplasia. Clinicopathological data of the patients of 
this study is given in the Table 1.
Quantitative real-time PCR
The fresh specimens from patients were collected to determine 
HDAC1 expression alterations in cancerous bladder tissues ver-
sus samples from healthy tissues. Only pathologically confi rmed 
tissues were considered cancerous and were taken to analysis.
Characteristic No of cases (%)
Sample number 88
Mean ± Standard deviation 65.5
Age (Year)
Range 42–90
Gender, n (%) 
Female
Male
12 (13)
76 (87)
Grading, n (%)
High grade Tumor
Low Grade Tumor
51 (58)
37 (42)
Muscle invasion, n (%)
Present
Absent
18 (20)
70 (80)
Tab. 1. Clinicopathologicalcharacteristics of bladder cancer patients.
Fig. 1. Agarose gel electrophoresis of PCR products stained by Ethid-
ium Bromide: Lines 1 to 4 show hHDAC1 fragments, amplifi ed from 
randomly picked cancerous bladder samples; Lines 5 to 7 show differ-
ent hHDAC1 products, amplifi ed from randomly picked normal blad-
der tissues. The original total RNAs amounts of all shown samples and 
their corresponding loaded materials are considered to be equal. The 
length of all PCR product is 263bp. Lane M shows 100bp DNA marker 
(Fermentase, Lithuania).
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Total RNAs were extracted from previously frozen Blad-
der tissues by TRIzol reagent (Invitrogen, USA) according to the 
manufacturer’s instruction. The quality and quantity of extracted 
RNAs were specifi ed by spectrophotometer (Kruss, Germany) at 
A260 and A280 nm wavelengths. The RNA sample integrities were 
confi rmed using measurement of relative sharpness of 28S to18S 
ribosomal RNA bands in agarose gel electrophoresis. One to two 
micrograms of total RNA from each sample were hybridized to 
Oligo(dT) primers and reverse-transcribed to cDNA by reverse 
transcriptase enzyme using cDNA synthesis kit (Thermo Scien-
tifi c, USA). Suitable and equal amounts of each single stranded 
cDNAs were prepared and then subjected to quantitative real-time 
Polymerase Chain Reactions in triplicate dilutions using SYBR 
Green PCR Master Mix in CFX96™ Real-Time PCR Detection 
Systems (Bio-Rad, USA). At least two human housekeeping genes 
of GAPDH and 18S rRNA were used to calculate and normalize 
relative gene expression data.
Before performing a real-time quantitative PCR, the standard 
PCR products amplifi ed using hHDAC1 primers were surveyed 
by either agarose gel electrophoresis against DNA sized markers 
or by sequencing, to determine the specifi city of PCR products 
amplifi ed (Fig. 1). The samples were also PCR amplifi ed with at 
least two set of GAPDH and 18S rRNA primers.
All primers were designed using either NCBI primer design 
tool (National Center f or Biotechnology Information, USA) or 
Primer3-BioTools (University of Massachusetts, USA). The nucleic 
acid sequences of the primers used in this study are mentioned in 
the Table 2. The thermo-cycling conditions of real-time qPCR for 
hHDAC1 primers were 95 oC for 10 min followed by 35 to 40 
cycles of 95 oC for 30s and 60 oC for 45 s.
For q-PCR, each sample was run in triplicate and each experi-
ment was performed two times. The mean threshold cycle (Ct) 
value for each assay was used for next calculations. This value is 
the PCR cycle number, at which the fl uorescence emission transits 
the threshold intersects with the exponential region of the amplifi -
cation curve by the CFX Manager Software (Bio-Rad). Compara-
tive Ct value method was the choice for the analysis of the results. 
The Ct values were normalized to the GAPDH and 18S rRNA 
expression values by subtracting Ct means of used housekeeping 
genes, from Ct means of target gene for each sample to get the ΔCt 
mean. The ΔCt mean values were then changed into fold change 
values, based on a hypothesis of doubling of PCR product every 
cycle, according to the manufacturer’s guidelines.
Statistical analysis
Quantitative data are presented as the mean ± SD (Standard 
Deviation). Statistical analyses were performed with the use of 
SPSS 16.0 software. The signifi cant differences between the con-
trol and test groups were analyzed by Student’s t-test. p value < 
0.05 was considered as statistically signifi cant.
Results
HDAC1 mRNA expression levels were quantifi ed in fresh 
human bladder cancer specimen using the relative quantifi cation 
method of real-time quantitative PCR. Brief clinicopathological 
characteristics of cancer patients are summarized in the Mate-
rial and Methods part. In this investigation, only pathologically 
confi rmed tissues were considered cancerous and were taken to 
analysis of HDAC1 mRNA expression. We found -after normal-
izing our target hHDAC1 mRNA expression quantities against 
those of corresponding housekeeping genes- that the mRNA lev-
els of hHDAC1 gene in malignant bladder tissues was clearly 
and signifi cantly higher than in those of normal healthy control 
samples i.e. 5.6 (0.41) vs. 1 (0.41) of relative expression (Fig. 2)
(p < 0.05, Student’s t-test). This means that hHDAC1 mRNA ex-
pression of cancerous tissues was raised more than 5 folds in com-
parison to that of normal healthy tissues. This result was obtained 
from randomly picked cancerous samples, regardless of samples’ 
characterization such as: their grads, genders or ages. The control 
samples were the healthy normal bladder parenchyma biopsies as 
described in the Material and methods. In addition to healthy biop-
sy samples, parts of normal bladder control samples were obtained 
through open transurethral prostatectomy. We were aware that 
these urothelial samples might not truly be free from infl ammatory 
process associated with prostatic hyperplasia and to address this, 
we did not use the corresponding tissues in the vicinity of bladder 
carcinomas as the main normal control samples for current calcula-
tion. However, as we were curiously speculating, the results using 
such corresponding tissues were expectedly similar to those values 
Primer Sequence Product size (bp)
HDAC1 F: 5’- TGGCCATCCTGGAAGACGA-3’
R: 5’- CATGACCGGCTTGAACCACC-3’ 263
GAPDH F: 5’- CAACTGCTTAGCACCCCTGG-3’
R: 5’- GCAGGTCAGGTCCACCACTG-3’ 280
18S rRNA F: 5’- CGGCTACCACATCCAAGGAA-3’
R: 5’- GCTGGAATTACCGCGGCT-3’ 187
F – forward and, R – reverse primers
Tab. 2. Primer names, corresponding sequences and product sizes.
Fig. 2. hHDAC1 mRNA relative expression in cancer specimen in com-
parison to normal human bladder tissues. The result shown in graph 
is normalized to at least two housekeeping genes expressions amounts. 
The control samples shown in this graph are normal biopsy samples. 
Each column shows the mean relative value of mRNA levels from all 
triplicate samples for Real Time Quantitative PCR. Bars represent 
the mean ± SD. A signifi cant difference in hHDAC1 mRNA expres-
sion level is shown between cancerous and normal tissues according 
to Student’s t-test (* p < 0.05).
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calculated using biopsy normal control samples (data not shown). 
No correlation with the patient genders, tumor muscle invasion, 
age or grading of the tumors were found when each of these dif-
ferent samples were studied separately comparing their relative 
expression levels to those of control samples (data not shown).
Discussion
Histone acetylation is a reversible process regulated by histone 
acetyl transferases (HATs) and histone deacetylases (HDACs). It is 
an epigenetic mechanism, which is involved in chromatin remod-
eling and translational regulation. Improper function of HDACs, 
including their overexpression, plays a vital role in developing of 
many type of cancers.
As HDAC inhibitors (HDACi) have been introduced as prom-
ising new agents for cancer therapy, there is a growing interest in 
studying of which type, class or member of HDACs might be in-
volved in emergence or development of various human cancer types. 
In particular, the class I of HDACs has been the center of attention 
(11). Previous proven reports indicating HDAC1 involvement in 
progression of different types of human solid cancerous tumors 
motivated us to study HDAC1 as candidate isoform of class I of 
HDACs enzymes in bladder carcinoma formation (4, 11). HDACs 
over-expression and the inhibitory effects of HDAC inhibitors on 
bladder cancer progression have been shown only in cell lines in 
vitro (18), however, no study has been conducted in HDAC mRNAs 
levels, including HDAC1 changes in vivo in clinical bladder cancer 
specimens. Expression of histone deacetylase 1, 2 and 3 proteins 
has recently been shown in clinical urothelial bladder cancer cases 
(19). However, to our knowledge; our work is the fi rst one to mea-
sure expression alteration of hHDAC1 transcripts in human bladder 
cancer tissues in vivo. Upregulation of hHDAC1 mRNA in vivo 
in our results indicates that HDAC1 may play an important role in 
human bladder cancer emergence/development. This conclusion 
has the support of other recent studies showing obvious correlations 
between overexpression of selected HDACs and several clinico-
pathological characteristics of some human malignancy such as 
breast cancer and, their tumor growth size and patient survival rates 
(11). Over expressed HDAC1 protein in colon, lung and gastric 
cancers cells contributes to an aggressive behavior and poor prog-
nosis (20–22). Likewise, alteration in HDAC1 expression levels 
were found in other human tumors including endometrial, ovarian, 
pancreatic cancers, as well as in hepatocellular carcinoma tumors, 
where the elevated expression of HDAC1 is usually associated with 
a poor prognosis (23–25). Strong HDAC1 overexpression in pros-
tate cancer has been accompanied by cancer progression and poor 
prognosis (12). In addition, the group of studies have analyzed the 
effect of different HDAC inhibitors in treatment of Bladder cancer 
cell lines: for example, HDAC inhibitors of MS-275 and TSA have 
been shown to be able to block the cell cycle in T24 cell line and 
induce apoptosis (18). Another study in 2012 showed that Valproic 
acid; a HDAC inhibitor decreased urothelial cancer cell prolifera-
tion (27). These studies suggest that HDACs expression may play 
an important role in bladder cancer occurrence. The recent study 
showed an improper increase in the expression and recruitment of 
HDAC1 results in aberrant regulation of specifi c genes involved 
in cell cycle and cell survival, leading to development of invasive 
adenocarcinoma of pancreas (4). Therefore, it has been suggested 
that HDAC1 is a potential prognostic biomarker and therapeutic 
target in pancreatic adenocarcinoma (4). Another study showed a 
decrease in colon cancer cells proliferation as the result of HDAC1 
gene knockdown (28). Additionally, a higher HDAC expression lev-
el has been associated with a poor prognosis in Gastric cancer (29).
Recently, the study of HDAC1 expression in testicular germ 
cell tumors revealed a signifi cant difference between seminoma- 
and non-seminomatous germ cell tumors, while no correlation with 
prognosis was shown (30). In 2011, Patani et al demonstrated that 
HDAC1 was overexpressed in breast cancer compared to normal 
or benign breast tissues. Moreover, higher HDAC1 expression 
was accompanied with higher grades of breast tumor and thus 
this study suggested that HDAC1 over expression is an important 
prognostic factor in breast cancer development (11). Up to now, 
most studies of HDAC1 expression in malignant tumors suggest 
a probable correlation between overexpression of this enzyme and 
tumor growth, progression and being a poor prognostic factor in 
these malignancies. Our fi nding in studying the human bladder 
cancer is in agreement with other studies of these types.
Collectively, our results showed HDAC1 mRNA level was 
elevated in bladder tissues of patients with bladder cancer. In ac-
cordance with the similar results of other researchers, the fi ndings 
in the bladder cancer cell line and in other types of cancer cells and 
tissues might indicate the importance of tight and proper regulation 
of HDAC1 gene expression for normal function of bladder cells 
in healthy people and the fact that an overexpression of this gene 
may trigger bladder cancer tumorigenesis in human.
An important strategy in developing of future cancer treatment 
involving HDAC inhibitors is the identifi cation of the most relevant 
HDACs causing tumorigenesis in a given tumor, in an individual 
patient and, subsequently the selection of proper combination of 
compounds from a library of selective HDAC inhibitors. Through 
this fi nding we may suggest that HDAC1 is a potential molecule 
to be targeted by a given anticancer HDACi drug and this study is 
the fi rst step in the pathway of constructing such selective scheme 
for HDACi bladder cancer therapy. The specifi c histone deacety-
lase inhibitors albeit remain to be discovered and further studies 
together with the results of this study may become useful tools for 
clinical applications such as: diagnosis, treatment and prognosis of 
bladder cancer, as well as designing and developing of new anti-
bladder cancer drugs. Since the HDACs family genes also include 
several other members, it would be important to clarify the associa-
tion between the expression level of the individual HDACs and the 
bladder cancer occurrence for each HDAC(s), in order to provide 
a better insight to the roles, in which each specifi c HDAC(s) may 
play in the development of bladder cancer. The work described in 
this study was focused on determining of just HDAC1 expression 
in bladder cancer. Likewise, this study only focused on HDAC1 
gene expression on mRNA level and thus, these results are not 
accompanied by immunochemistry data.
Although for heterogeneous urothelial carcinoma it might be 
considered unusual, we were not able to fi nd a signifi cant differ-
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ence between HDAC1 expression in different patient genders and 
ages when each of these different samples was studied separately 
comparing to their relative expression levels to those of the control 
samples (data not shown). These results refl ect a quick hHDAC1 
possible involvement in developing human bladder cancer tu-
morigenesis and thus, we did not follow-up patients’ clinical data 
in long term to see whether there is any correlation between the 
mRNA expression levels with survival rates and/or prognosis. De-
spite, the result of this study is the fi rst reported of HDAC1 mRNA 
over-expression in clinical tissues of bladder cancer in vivo and 
suggests that overexpression of the human HDAC1 may be cor-
related with the incidence of bladder cancer in human.
Learning points
As an “epigenetic” molecule, HDAC1 of class I of HDACs 
has a proven transcriptional regulatory role in cell-cycle arrest/
proliferation in both cancerous bladder cell lines in vitro and in 
vivo in human clinical specimens, at mRNAs level.
This fi nding is interesting because it shows that HDAC1 could 
play as a potential diagnostic marker and can be considered as the target 
molecule for the treatment with anti-cancer drugs of Histonedeacet-
ylas inhibitors (HDACi) in further bladder cancer treatment.
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